Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US‐licensed Humulin® N formulation in healthy subjects: Results from the RHINE‐2 (Recombinant Human INsulin Equivalence‐2) study
Sign Up to like & getrecommendations! Published in 2023 at "Diabetes"
DOI: 10.1111/dom.14994
Abstract: To establish the pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of proposed biosimilar Insulin N (Biocon's Insulin‐N; Biocon Biologics Ltd., Bangalore, India) and US‐licensed Humulin® N (Humulin‐N; Eli Lilly and Company, Indianapolis, IN, USA) in healthy… read more here.
Keywords: pharmacodynamic equivalence; biosimilar insulin; equivalence; pharmacokinetic pharmacodynamic ... See more keywords